Emergent Biosolutions INC Schedule 13G passive stakes

American Century ETF Trust, American Century Investment Management, Inc., American Century Companies, Inc., and Stowers Institute for Medical Research have jointly filed a Schedule 13G, disclosing beneficial ownership of over 5% of Emergent BioSolutions Inc. common stock.

Vanguard Capital Management has reported a 4.92% ownership stake in Emergent BioSolutions Inc., holding 2,540,945 shares.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 9.0% in Emergent BioSolutions Inc. as of June 30, 2026.

Vanguard Capital Management has filed a Schedule 13G reporting a 5.04% beneficial ownership stake in Emergent BioSolutions Inc.

Dimensional Fund Advisors LP has disclosed a beneficial ownership of 5.3% of Emergent BioSolutions Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Emergent BioSolutions Inc. following an internal realignment.

State Street Corporation has reported a 5.1% beneficial ownership stake in Emergent BioSolutions Inc., holding 2,696,375 shares of common stock.

The Vanguard Group filed an amended Schedule 13G, disclosing its beneficial ownership of 6.76% of Emergent BioSolutions Inc. common stock.

BlackRock, Inc. has reported a 7.3% beneficial ownership stake in Emergent BioSolutions Inc., holding 3,977,535 shares of common stock as of June 30, 2025, for passive investment purposes.